Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 12/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | MC1R | Q01726 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551732 | 1.00 | MC4R (0.36) | MC4RLMNATP53GRM5MC5R | |
| SCHEMBL8292853 | 0.90 | KMT2A (0.46) | LMNATP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL1827719 | 0.90 | KMT2A (0.46) | LMNATP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2247475 | 0.89 | LMNA (0.42) | LMNATP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2248042 | 0.87 | MAPT (0.38) | MC4RLMNATP53MAPTSMN1; SMN2 | |
| SCHEMBL2250334 | 0.85 | ME2 (0.40) | LMNATP53MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2249495 | 0.85 | ACACB (0.41) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL8270754 | 0.85 | ACACB (0.41) | LMNAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1828390 | 0.84 | ALDH1A1 (0.41) | TP53MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2247755 | 0.83 | ADORA2A (0.35) | LMNATP53MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | MC4R 3524/4885LMNA 1655/4885TP53 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.